The international weekly science journal Nature recently published findings from a large, multi-country study identifying 108 genes, 83 of these unknown before, as contributing to schizophrenia risk. These findings more than triple the number of genetic associations previously known for this disease. Pfizer, through an agreement with the Broad Institute, contributed samples to the investigation, which was conducted by the Psychiatric Genomics Consortium (PGC), a collaboration of more than 80 institutions that analyzed data for more than 150,000 adult subjects.
José Carlos Gutiérrez-Ramos, Group Senior Vice President of BioTherapeutics Research and Development discusses how Pfizer’s Centers for Therapeutic Innovation is working to discover potential medicines by bringing together key stakeholders early in the process, including disease foundations and academic centers.
Pfizer and a number of its industry peers, including Janssen Research & Development, L.L.C. and Sanofi, have committed 26 new agents to The National Institutes of Health (NIH) and its National Center for Advancing Translational Sciences (NCATS) to expand its Discovering New Therapeutic Uses for Existing Molecules program.
Pfizer Opens New State-of-the-Art Research and Development Site in Cambridge, Massachusetts: Bio-Innovation Hub Represents Significant Step in Pfizer’s Long-Standing Commitment to the Area
Dr. Jack Watters, M.D., Pfizer’s VP for External Medical Affairs, took the stage this week at the 12th International Federation on Ageing (IFA) Global Conference on Ageing in Hyderabad, India. Watters’ keynote address on healthy and active aging highlighted the importance of public-private partnerships to ensure the health and well-being of older people. He also emphasized that aging is affecting more than just the lives of those who are older themselves, stating that society should do more to foster inter-generational engagement.
A critical part in the process of bringing new therapies to patients is clinical development, the study of potential new therapies in humans.
Pfizer is finding new ways to develop therapies to improve and extend the lives of patients.
You may have noticed that Pfizer.com looks a little bit different. We're updating our design a bit, and we thank you for bearing with us as we make this change.
Pfizer Neuroscience Scientist Mercedes Benya explains the importance of the blood-brain barrier and the bypassing approaches being investigated in order to treat diseases of the central nervous system.
Worldwide Medicinal Chemistry's (WWMC) innovative use of structure-based drug design (SBDD) and physical properties-based optimization (PPBO) helps Pfizer deliver on the pipeline by allowing chemists to analyze complex data.
Michael Ehlers, Chief Scientific Officer of Pfizer's Neuroscience Research Unit (RU), will be awarded the prestigious Thudichum Medal by the Biochemical Society, the U.K.'s largest discipline-based professional and academic society in the biosciences.
Pfizer is one of the key partners in a newly launched international consortium of scientists that represents one of the largest ever academic-industry research collaborations aimed at finding new methods for the development of drugs for autism spectrum disorders.
Two Pfizer colleagues in Worldwide Research & Development were named "We Work for Health Champions" by industry trade organization PhRMA (Pharmaceutical Research and Manufacturers of America).
The "Alzheimer's Challenge 2012" calls for inventive concepts to help improve the diagnostic identification and tracking of Alzheimer's disease and will provide cash prizes for the best submissions.
Elected for a three-year, Das will lead the premier organization worldwide of all scientists dedicated to the discovery, development and manufacture of biotechnology-related pharmaceutical products and therapies through advances in science and technology.
Life Science Leader magazine featured an interview with Pfizer's John Hubbard, Head of Development Operations, on how Pfizer's strategic partner model evolved and how it is going to help spur innovation.
The Day (of New London) featured a front page story about the evolving role of Worldwide Research & Development's Groton site, which is being transformed into the company's drug-development hub: the Center for Discovery and Development Sciences.
Pfizer has entered into a 10-year lease agreement with the Massachusetts Institute of Technology (MIT) for more than 180,000 square feet in a new building under development in Cambridge, Massachusetts.
Pfizer and the Massachusetts Institute of Technology last week held the official groundbreaking of the new location of Pfizer's Cardiovascular, Metabolic and Endocrine Diseases and Neuroscience research units at Kendall Square in Cambridge, Mass.
Hakan Sakul, Executive Director and Head of Diagnostics within WRD's Development Operations organization, was honored with the "Chairman's Award in Personalized Medicine".
Here is a recap of some of the most popular Think Science Now (TSN) blog posts of 2011.
Michael Ehlers, Chief Scientific Officer of Pfizer's Neuroscience Research Unit (RU), discusses the challenges and opportunities in the field of neuroscience research in a special advertorial featured in the latest edition of the journal Nature.
Pfizer colleagues volunteered their time over a recent weekend to share the wonders of science with visitors to the San Diego Festival of Science and Engineering Expo Day.
Pfizer is a pioneering partner in a National Institutes of Health (NIH) collaborative program that will match academic researchers with dozens of pharmaceutical industry-owned molecules.
Two Pfizer colleagues were recognized by the Asian American Business Development Center (AABDC) as among the 2012 "Outstanding 50 Asian Americans in Business."
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.
Current Stock Price
|%Change||.||52 Wk. High||.|
|Day High||.||52 Wk. Low||.|
|Day Low||.||Mkt. Cap(Mil)||.|
Online Pfizer Press Kit
Our press kit provides information that might help you write stories or simply find out more about Pfizer.